Guidance met, but acute recovery unproven

Delivered ₹4,030.6 Cr (+12.9%), OPM 26.2%. Rounding match.

Delivered ₹574.1 Cr (+29.1%), NPM 14.1%. Match.

OPM 26.2%, consistent with 26.3% EBITDA claim.

Chronic portfolio grew 15.8% YoY with volume at 4.7% (up 220 bps). Share gain evidenced.

Achieved 26.3%, within range at top. No cut or raise.

Q1 at 12.9% (low double-digit). Domestic +11% excl. CHC. Volume recovery 4.7% suggests momentum building.

Up from 48 days (Q1 FY26) due to elevated inventory buffering price increases. Management expects rationalization; no concrete timeline given.

CHC 3.8% growth (weak). Modern trade/e-com +38%. Market share claim unverified from transcript; management references 'increased' but no data.

Prior: aiming for 1.3–1.7x IPM growth. Current: 'we never said we'd beat IPM' (Rajeev). Now guiding for double-digit (matching IPM). This is a tactical step-back.

Was expected to launch in first wave. Delayed due to attrition cleanup + competitive pricing risk. Now running as therapy bundle (gynaec + diabetes + supplements), not standalone molecule. Near-term NIL contribution.

No change. Achieved 26.3% in Q1. Reaffirmed despite West Asia cost headwinds, suggesting confidence in gross margin defense.

Q1 at 4.9% (below guidance). Biotech facility added/enhanced; no new facility announcements. Capex timing flexibility signaled.

Q1 softness (3.8%) acknowledged; guidance for Q2+ is 'high single-digit to double-digit'. Market share gains in Manforce/Preganews/Gas-o-fast noted. Modern trade +38% YoY compensating for cash & carry exit.

Already returned to double-digit growth. Quality improved: Chronic +15.8%, Acute 10.9%, BSV strong. Four structural levers: Chronic mix 40%→50%, hospital penetration expansion, new division Vistar, underpenetrated states. Will progressively outperform.

Last year early teens, this quarter 21%. Guidance high double-digit (high teens). Domestic 17%, international 25%. Well-spread across segments.

Expect to come down by year-end due to price advantages. Inventory slightly above normal; rationalization expected in coming quarters.

Only caveat: West Asia crisis commodity/dollar headwinds. Taking conservative approach. Overall EBITDA guidance unchanged 25.5–26.5%.

Cash EPS is after depreciation, amortization, and impairment—cash portion. Roughly 50% allocation to acquisition-related. Will clarify offline.

Covered market improved: FY21 56%→FY26 74%. Launched insulin, DPP-4, SGLT2, respiratory inhalers, CNS in-licensed. No meaningful change in relative coverage. Rank improved from 10→7 in diabetes.

Not cautious, strategic. Let 35–40 brands compete, massive price war. Taking therapy approach instead (gynaec + diabetes + supplements). Avoiding resource waste on hypercompetitive molecule. Launched in two segments already.

Launches very strategic. Make each big (Vonoprazan #1, Empagliflozin top 3). Selective, not volume. This is strategic move, not a lag to close.

Aspiration is there, will take time. CNS is specialist, textbook brand. Building gold CNS portfolio. Key is entry to specialist doctors first.

Acute: -2.5% (Q2)→13.6% (Q1). Gastro, Vitamins, Gynaec sequential improvement. Attrition dropped significantly, back to normal. Recovery on strong foundation.

Market dynamic: general trade losing to e-commerce/modern trade. Same consumer, different channels. Modern trade/e-com share 11%→15%, +38% growth compensating. Overall market softer.

Never claimed first few companies to launch. Couldn't launch in first phase due to company corrections (attrition). Strategic call to avoid price war. Launched in two segments with therapy approach (KOL-led).

BSV +25%, Mankind+BSV guidance high teens. US launches, currency tailwind 12–13%. Ophthal product (prior one-off) now in base since FY25.

FY26: 50–50. This year expected similar range ±2%.

High single-digit to double-digit.

BSV run independently both domestic/international. Tweaked management, added biotech facility. Gynaec coverage 33k→37k, IVF 80% reach, +35% growth. International: new approvals (Russia), upcoming FSH approvals.

60% of business from Acute. Relationship and face value matter. Removed people 18 months back, recovery on strong foundation. Prescription-driven policy. Never claimed to beat IPM. Double-digit growth target, EBITDA 25.5–26.6%.

Q1 delivered 12.9%. Domestic (excl. CHC) 11%, BSV strong, international 29%. Structural levers (Chronic mix, acute recovery, Vistar launch, hospital expansion, underpenetrated states) support sustain.

Q1 achieved 26.3% (mid-range, near top). Gross margin guidance 71%+ (conservative vs 72.8% Q1 achieved) due to West Asia cost headwinds. Operating leverage from fixed cost absorption.

Conservative guidance accounts for commodity/dollar inflation. Price increases already taken; expect some margin compression from cost inflation, but offset by Chronic mix and efficiency.

Q1 at 4.9% (below guidance). Biotech facility added/enhanced. Timing flexibility signaled; second half expected to have higher spend.

Acute 60% of portfolio; recovered to 10.9% but still below historical 1.3–1.7x IPM. Relationship-based (face-to-face matters). 18-month cleanup may not be sufficient.

35–40 brands launched; management chose to delay and avoid price war. Therapy bundling (gynaec+diabetes+supplements) untested. If early movers capture share and pricing stabilizes, Mankind's late entry may face difficult economics.

WC days increased from 48 to 52 due to elevated inventory buffering price increases. If dollar/commodity costs remain high through FY27, normalization may be delayed, impacting cash flow.

Q1 achieved 72.8%, but management guided conservatively to 71%+ citing West Asia geopolitical risk. If oil/shipping costs spike or conflict escalates, gross margin could compress to 70% or below.

Q1 Consumer Healthcare growth soft (3.8%). Cash & carry discontinuation to protect general trade didn't yield expected higher GT sales. Modern trade/e-com up 38% but from lower base. Channel mix transition uncertain.